Sanegene Bio's Complement C3-Targeting RNAi Drug SGB-9768 Completes First-in-Human Dosing in China Phase I Trial

SGB-9768, Developed by SANEGENEBIO, for the Treatment of Complement-Mediated Kidney Diseases: A Potential "First-in-China, World-Leading" siRNA Drug Targeting Complement C3

RNAi Therapy as an Advanced Treatment Modality, Can Provide Patients with More and Better Treatment Options. siRNA Drugs Targeting Complement C3 Are Expected to Overcome Existing Treatment Limitations for AdultsIgA Nephropathy, C3 glomerulopathy, and immune complex-mediated membranoproliferative glomerulonephritis, etc., bring clinical benefits to patients with kidney diseases.

Dr. Yuyan Jin, Senior Vice President of Clinical and Non-clinical at SANEGENEBIO, stated:“The successful dosing of the first subject in China for SGB-9768 marks an important milestone for this project. The rapid initiation and advancement of this study are attributed to the strong support from the Research Center of Huashan Hospital Affiliated with Fudan University, as well as the joint efforts of the project team. This also demonstrates that SANEGENEBIO is at the forefront globally in the development of innovative siRNA drugs for treating complement-related diseases. The drug utilizes the company’s proprietary GalNAc liver delivery platform, ensuring good safety. We look forward to the performance of SGB-9768 in subjects, hoping it can revolutionize the clinical treatment landscape of complement-mediated renal diseases worldwide and provide patients with better therapeutic options.”